Related Experiment Video
Updated: Jan 8, 2026
15:27
Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
Published on: April 17, 2017
21.4K
Addressing nonspecific interactions in a Gyrolab anti-drug antibody (ADA) assay: a case study on method optimization
Eliza Kęsy-Siwik1,2, John Chappell3, Dorota Jaros4
1Research and Development Department, Mabion S.A., Konstantynów Łódzki, Poland.
Bioanalysis
|December 16, 2025
Summary
Optimizing a Gyrolab immunoassay improved detection of anti-drug antibodies (ADAs) against MabionCD20 in rheumatoid arthritis patients. Adjusting buffer conditions eliminated nonspecific interactions, enhancing assay reliability for immunogenicity testing.
Area of Science:
- Biochemistry
- Immunology
- Assay Development
Background:
- Anti-drug antibodies (ADAs) can compromise therapeutic drug efficacy and patient safety.
- Sensitive and drug-tolerant immunoassays are crucial for accurate ADA detection.
- Nonspecific interactions can negatively impact assay performance and repeatability.
Purpose of the Study:
- To re-optimize a Gyrolab immunoassay for detecting ADAs against MabionCD20 (a rituximab biosimilar).
- To eliminate nonspecific interactions affecting assay repeatability in rheumatoid arthritis patient serum.
- To enhance assay drug tolerance and suitability for clinical validation.
Main Methods:
- Evaluated multiple strategies to mitigate nonspecific interactions.
- Included additional washing steps and increased buffer ionic strength.
- Systematically modified assay protocol, focusing on neutralization buffer molarity and pH.
Main Results:
- Reducing neutralization buffer molarity and increasing its pH effectively eliminated unwanted interactions.
- Improved assay repeatability and drug tolerance parameters were observed.
- The optimized assay demonstrated enhanced performance and suitability for validation.
Conclusions:
- Optimization of buffer composition and pH successfully resolved nonspecific interaction issues.
- The enhanced Gyrolab immunoassay offers a robust and reliable method for ADA detection.
- This optimized assay supports immunogenicity assessment in clinical development programs.
